MYC and plasma cell myeloma: This compound inhibited the proliferation of RPMI-8226 and U266 multiple myeloma cells in vitro at concentrations in the 20–40 μM range, induced cell cycle G2 phase arrest and triggered their apoptosis by disturbing the stability of the Myc protein, while Myc mRNA levels were unaffected.